Implication des endothélines et de leurs récepteurs vasculaires dans la circulation pulmonaire en condition contrôle et pathophysiologique
The endothelin (ET) system is activated in pulmonary arterial hypertension (PAH); indeed, increased plasma levels of ET-1 were detected in patients with various forms of PAH and in various experimental models. The therapeutic value of pharmacological blockade of ET receptors has been demonstrated in various animal models and led to the current approval and continued development of these drugs for the therapy of human PAH. Whether the net effect of either selective ETA receptor blockade or combined ETA/ETB receptor blockade provides greater therapeutic benefit remains a subject of debate. Although the ET system contributes to PAH, we currently incompletely comprehend which local modifications of this system occur as a consequence of PAH, particularly in small resistance arteries, and how this could affect the pharmacological response to ET receptor antagonists. The purpose of the first study was therefore to evaluate potential modifications of the pharmacology of the ET system in rat pulmonary resistance arteries from monocrotaline-induced PAH. Our results reveal striking changes in pulmonary vasculature sensitivity to ET receptor antagonism in PAH that may be related to a reduction in ETB receptor expression. A better understanding of the exact role played by both ETA and ETB receptors on pulmonary resistance arteries might contribute to optimization of PAH treatments. Therefore the aim of the second study was to clarify the role played by both ETA and ETB receptors in ET-1 induced pulmonary vasoconstriction using an antisense (AS) oligonucleotide ex vivo treatment. In this study we have demonstrated that ETA and ETB receptors can form heterodimers in pulmonary resistance arteries. Furthermore, suppression of ETA receptors potentiated the response to ET-1 suggesting that in control condition the ETA receptor has an inhibitory action on the ET-1 induced pulmonary vasoconstriction induced by the stimulation of the ETB receptor.  Although the deleterious effects of ET-1 on the pulmonary circulation are well established, only a few studies have focused on ET-3 in PAH. Therefore, the purpose of the last study was to evaluate the potential implication of ET-3 in MCT-induced PAH and evaluate the roles of ETA and ETB receptors on ET-3-induced pulmonary vascular reactivity. In control condition, the use of a combination of both ETA and ETB receptor antagonists is necessary to reduce the ET-3 induced pulmonary vasoconstriction. In PAH, we found an increased ET-3 plasma levels and a modification of the pharmacological profile of ET receptor antagonists. Indeed, the use of either the ETA receptor antagonist or the dual antagonist was able to reduce the ET-3 response.   The results from these three studies suggest that it is preferable to use a dual antagonist in the treatment of PAH. Indeed, (1) in PAH the use of a dual antagonist is as effective as the use of a selective ETA receptor antagonist (2) ETA and ETB receptors can form heterodimers in pulmonary resistance arteries and (3) ETB receptor plays an important role in the ET-1 induced pulmonary vasoconstriction, suggesting that it is necessary to block both receptors to reduce the ET-1 induced pulmonary vasoconstriction. Keywords: endothelin-1, endothelin-3, pulmonary resistance artery, receptor, endothelin receptor antagonist, dimerisation, phosphorothioate pulmonary arterial hypertension
Endothelin-1 Endothelin-3 Pulmonary resistance artery Receptor Endothelin receptor antagonist Dimerisation Phosphorothioate Phosphorothioate Pulmonary arterial hypertension